HiFiBiO Therapeutics, a Boston-Paris-Shanghai company, has formed an immune modulation JV, Victa Biotherapeutics, with Vikas P. Sukhatme, MD. Using Dr. Sukatme’s research, the JV will develop drug candidates based on myeloid-derived suppressor cells (MDSCs). HiFiBiO will apply its single-cell profiling expertise to identify first-in-class antibodies for various cancer indications. HiFiBiO develops novel antibody drugs that treat cancer and autoimmune disorders. Victa has an option to license IP for any candidates that show promise as therapies.
Source: China Biotoday
